Improved understanding of the molecular mechanisms responsible for the progression from a "nonpathogenic" steatotic state to Non-Alcoholic Steatohepatitis is an important clinical requirement. The cell death-inducing DFF45 like effector (CIDE) family members (A, B and FSP27) regulate hepatic lipid homeostasis by controlling lipid droplet growth and/or VLDL production. However, CIDE proteins, particularly FSP27, have a dual role in that they also regulate cell death. We here report that the hepatic expression of CIDEA and FSP27 (α/β) was similarly upregulated in a dietary mouse model of obesity-mediated hepatic steatosis. In contrast, CIDEA expression decreased, but FSP27-β expression strongly increased in a dietary mouse model of steatohepatitis. The inverse expression pattern of CIDEA and FSP27β was amplified with the increasing severity of the liver inflammation and injury. In obese patients, the hepatic CIDEC2 (human homologue of mouse FSP27β) expression strongly correlated with the NAFLD activity score and liver injury. The hepatic expression of CIDEA tended to increase with obesity, but decreased with NAFLD severity. In hepatic cell lines, the downregulation of FSP27β resulted in the fractionation of lipid droplets, whereas its overexpression decreased the expression of the anti-apoptotic BCL2 marker. This, in turn, sensitized cells to apoptosis in response to TNF α and saturated fatty acid. Considered together, our animal, human and in vitro studies indicate that differential expression of FSP27β/CIDEC2 and CIDEA is related to NAFLD progression and liver injury.
Results

Hepatic expression of CIDEA, FSP27α and β increased with obesity-induced hepatic steatosis.
We first evaluated the hepatic expression levels of CIDEA, CIDEB and FSP27α and β in dietary mouse models of obesity and hepatic steatosis. After 33 weeks of high-fat diet (HFD), the wild-type C57BL/6 (Wt) mice developed obesity ( Supplementary Fig. 1A ), severe hepatic steatosis ( Supplementary Fig. 1B ,C) and hepatic injury as assessed by ALT activity ( Supplementary Fig. 1D ). The hepatic expression levels of CIDEA and FSP27 α and β were robustly increased upon 33 weeks of HFD at both the mRNA ( Fig. 1A) and protein (CIDEA and FSP27) ( Fig. 1B) level. Hepatic expression of CIDEA, FSP27 α and β also correlated with hepatic steatosis and liver injury ( Fig. 2A,B) . These occurred at the same extent as evaluated by the FSP27 α /CIDEA and FSP27 β/CIDEA ratios which did not change with hepatic steatosis and did not correlate with liver injury (Figs 1C, 2C ). The hepatic expression of FSP27α and β were similarly increased in obese mice ( Fig. 1C : relative expression of FSP27β versus FSP27α). Even though it is robustly expressed in the liver (data not shown), hepatic expression of CIDEB did not change with obesity or hepatic steatosis (Fig. 1A ). Steatosis and/or obesity were thus associated with the upregulation of the hepatic expression of CIDEA, FSP27α and β.
Differential expression of CIDEA and FSP27β is related to the severity of the MCDD-mediated steatohepatitis.
To subsequently investigate the behavior of the CIDECs in response to the progression and the severity of the NAFLD, we monitored their hepatic expression in wild-type mice fed a diet deficient in methionine and choline (MCDD) for 2 and 7 weeks. At 2 weeks, mice developed moderate hepatic steatosis with mild hepatic inflammation and liver injury ( Supplementary Fig. 2 ). The long-lasting MCDD challenge (7 weeks) aggravated the liver complications with severe steatosis (from 50 ± 8% at 2 w to 81 ± 3% at 7 w, p = 0.0201), inflammation (from 9 ± 3 foci/10 fields at 2 w to 77 ± 7% at 7 w, p = 0.0024) and liver injury (ALT activity from 51 ± 7 U/L at 2 w to 282 ± 42 U/L at 7 w, p = 0.0024) ( Supplementary Fig. 2 ). Hepatic CIDEA decreased in concert with the severity of the NAFLD at both the mRNA and the protein level (Fig. 3A, D) . Its hepatic expression negatively correlated with hepatic inflammation (number of inflammatory foci) and liver injury (ALT activity) after 7 weeks of MCDD ( Fig. 4A ). In contrast, the hepatic FSP27β was robustly augmented as NAFLD severity increased, from a 13-fold (±3) increase at 2 weeks to a 28-fold (±2) increase after 7 weeks of MCDD ( Fig. 3B, D) . Hepatic FSP27β also correlated with inflammation and liver injury after 7 weeks of MCDD (Fig. 4B ). The increased FSP27 expression was mainly caused by the upregulation of FSP27β since FSP27α expression tended to decrease ( Fig. 3B ). This inverse regulation pattern for CIDEA and FSP27β expression was better illustrated by the FSP27β/ CIDEA ratio, with a 21-fold increase at 2 weeks versus a 48-fold increase at 7 weeks, p = 0.017 ( Fig. 3C ). This ratio also strongly correlated with hepatic inflammation and liver injury (Fig. 4C ). The severity of the steatohepatitis was thus associated with an opposite expression of CIDEA and FSP27β.
Hepatic CIDEC2 correlated with the severity of the NAFLD in obese patients. To address the human relevance of our findings, we examined the relationship between hepatic CIDEA, CIDEB, CIDEC1 and CIDEC2 expression and the NAFLD progression from normal liver to steatosis and subsequent NASH in human liver biopsies from morbidly obese patients seeking for bariatric surgery. Patients were classified into 3 groups: without NAFLD, with hepatic steatosis (Steatosis) and with NASH (NASH) (assessed on the basis of three histopathological features steatosis, lobular inflammation and hepatocellular ballooning; Table 1 , Supplementary Fig. 3 and Supplementary Methods). Liver mRNA levels of CIDEC2 were progressively upregulated with hepatic steatosis and subsequent NASH (Fig. 5A ). This expression correlated with NAFLD features including hepatic steatosis, NASH and NAFLD activity score (NAS) (Fig. 5B ). Hepatic CIDEC2 also correlated with hepatic injury as assessed www.nature.com/scientificreports www.nature.com/scientificreports/ by ALT activity (Fig. 5C ) and serum levels of keratin 18 (hepatocyte death marker) and caspase-generated keratin 18 fragment (hepatocyte apoptotic marker) 24, 25 (Fig. 5C ). As reported in the mouse model of steatohepatitis, the upregulation of CIDEC is mainly related to CIDEC2 expression since CIDEC1 is not altered (data not shown). In contrast, hepatic CIDEA tended to increase in obesity (lean versus obese patients without NAFLD) and then to decrease in NAFLD ( Fig. 5A ). This relationship was significantly amplified when the CIDEC2/CIDEA ratio was evaluated (with NAS: r s = 0.861, p < 0.001, n = 26)( Supplementary Fig. 3 ). Consistent with our animal results, the CIDEB expression was not modified with obesity and NAFLD ( Fig. 5A ) in human studies.
Down regulation of FSP27β resulted in a decreased lipid droplet size in mouse hepatocytes.
Since FSP27β is localized on the surface of lipid droplets and is known to suppress lipolysis 18 , we therefore investigated if altered FSP27β expression could affect hepatocyte lipid droplet synthesis. The down-regulation of FSP27β in AML12 hepatocytes ( Fig. 6A ), the main isoform expressed in hepatocyte ( Fig. 6A ), modified the size distribution of the lipid droplets in response to oleic acid ( Fig. 6B , C). The number of small lipid droplets increased, while the number of large lipid droplets decreased. FSP27β expression could thus be involved in the development of hepatic macro-steatosis.
Overexpression of FSP27β sensitized hepatocytes to cell death in response to TNFα and palmitic acid and led to decreased BCL2 expression. FSP27, in addition to regulating lipid droplet development, could also mediate apoptosis in an expression-dependent fashion 21, 22, 26 . Furthermore, our human and experimental data strongly suggested that the expression level of FSP27β (mouse)/CIDEC2 (human) was associated with NAFLD progression and correlated with liver injury in NAFLD (Figs 2, 4 and 5). As TNFα was strongly upregulated in NASH liver, strongly correlated with ALT activity (HFD mice: r s = 0.666, p = 0.007, n = 15; 7 weeks MCDD mice: r s = 0.879, p = 0.002, n = 9) and well reported to mediate hepatocyte death [27] [28] [29] [30] , we first (Fig. 7B ). This slight effect could be explained by the low percentage of transfected cells (20.48 ± 2.84% of GFP + cells; n = 4). Interestingly, this cell death was associated with a decrease in anti-apoptotic BCL2 expression ( Fig. 7A ). Furthermore, these effects were further amplified in response to TNFα and TNFα with Acti D in HEPG2 cells overexpressing FSP27β, versus control HEPG2 hepatocytes ( Fig. 7B ). We then evaluated the effect of the FSP27β overexpression on HEPG2 viability in response to saturated fatty acid (palmitic acid), key player in hepatocyte lipotoxicity. Again, the cell viability was further decreased in response to palmitic acid in HEPG2 cells overexpressing FSP27β, versus control HEPG2 hepatocytes ( Fig. 7C ). By regulating hepatic steatosis and liver injury, FSP27β thus plays a key role in the NAFLD progression to more severe complications, i.e., NASH.
Discussion
Here we report differential hepatic expression of CIDEA and FSP27β/CIDEC2 in response to increasing NAFLD severity. Hepatic FSP27β/CIDEC2 expression was not associated with obesity, but progressively increased with hepatic steatosis and subsequent steatohepatitis in mouse and human studies, respectively. In contrast, hepatic CIDEA increased with obesity but its hepatic expression tended to decrease with the severity of the steatohepatitis. The FSP27β/CIDEC2 to CIDEA ratios better illustrated this opposing regulatory pattern and strongly www.nature.com/scientificreports www.nature.com/scientificreports/ correlated with hepatic inflammation (number of inflammatory foci in mouse studies, and NASH and NAS in patients) and liver injury (ALT activity in mouse and human studies).
As previously demonstrated, the hepatic expression of CIDEA is increased in a mouse model of diet-induced obesity and hepatic steatosis 9, 10 . This upregulation could be more closely associated with obesity than hepatic steatosis. Indeed, its hepatic expression tended to increase in obese patients without liver complications and metabolic syndrome, compared to lean patients. It has also been reported that the hepatic expression of CIDEA correlates with body mass index in obese patients 31 . CIDEA polymorphism has also been associated with obesity in human 32, 33 , although this could be more closely related to its role in adipose tissue. The role of CIDEA in hepatic triglyceride accumulation and lipid droplet formation has been clearly demonstrated and its targeting (overexpression and down regulation) regulates hepatic steatosis in obese mice 10 . In our cohort of obese patients and in a mouse model of steatohepatitis, the hepatic expression of CIDEA decreased with the severity of liver injury and steatohepatitis. However, it is important to emphasize that this is specific for CIDEA. Indeed, other important elements in the regulation of lipid droplet synthesis, such as PLIN5 and PNPLA2, are still upregulated in the fatty liver tissue of MCDD mice (after 7 weeks of MCDD: 2.3-fold increase for PLIN5, p = 0.0142; 3.13-fold increase for PNPLA2) and strongly correlate with hepatic steatosis in obese patients (PLIN5: r s = 0.698, p < 0.001, n = 30; PNPLA2, r s = 0.767, p < 0.001, n = 30). Since CIDEA expression is mainly dependent on SREBP1c 9,10 and Similarly, the progressive upregulation of FSP27β/CIDEC2 with the progression of NAFLD could be a marker but also an important player. This gradual increase is more closely associated with FSP27β/CIDEC2 than FSP27α/ CIDEC1 in mouse and human studies. Xu et al., who first described the β isoform of FSP27 in fatty liver, also reported its upregulation in mouse models of diet-induced obesity and steatohepatitis and in human studies 18 . The "mild" upregulation of FSP27β could be related to hepatic steatosis as we and other groups have previously reported ( Fig. 1 and 13-17 ). Furthermore, we have observed that its down-regulation in hepatic cells promoted the fractionation of lipid droplets in response to oleic acid. In accordance with this, it has been reported that the down-regulation of FSP27β in steatotic liver tissue resulted in reduced accumulation of hepatic triglycerides and lipid droplets 17 .
The strong upregulation of FSP27β/CIDEC2 could be more closely related to steatohepatitis and liver injury. Hepatic expression of FSP27β/CIDEC2 shows a strong correlation with liver injury as evaluated by ALT activity (in mouse and human studies) and a serum marker of hepatocyte apoptosis (in humans). With the increasing severity of the steatohepatitis, hepatic expression of FSP27β rises to a 28-fold (±2) increase in 7 weeks MCDD mice, versus a 13-fold (±3) increase in 2 weeks MCDD and HFD mice. We also observed that overexpression of FSP27β sensitized hepatocytes to cell death mediated by cytokine (TNFα) and saturated fatty acid (palmitic acid). Several groups have reported that FSP27 is a potent apoptotic inducer via the activation of the pro-apoptotic caspases, which trigger both the release of cytochrome c from mitochondria and DNA fragmentation [20] [21] [22] [23] . This apoptotic role for FSP27 was found to require the CIDE-C domain. In line with this, overexpression of CIDE-C domain containing FSP27α also sensitized hepatocytes to cell death mediated by cytokine (TNFα) www.nature.com/scientificreports www.nature.com/scientificreports/ ( Supplementary Fig. 4 ), while FSP27α expression tended to decrease with the severity of the steatohepatitis. Interestingly, the same domain of FSP27 also mediated its localization to lipid droplets and its interaction with CIDEA 21, 35 . The inverse patterns of regulation for the hepatic expression of CIDEA (down-regulated) and FSP27β (up-regulated) is robustly amplified with the NAFLD progression (FSP27β/CIDEA ratio ranges from 1.6 ± 0.6 in simple steatosis (HFD mice) to 21 ± 2 in steatohepatitis (2 weeks MCDD mice) and 48 ± 7 with advanced steatohepatitis (7 weeks MCDD mice)). This opposing regulatory pattern could also modify the role of the C domain of FSP27β, which could be more involved in the alteration of lipid droplets or the initiation of the apoptotic program, rather than binding with CIDEA.
Interestingly, the role of FSP27/CIDEC has recently been investigated in alcoholic steatohepatitis. Xu et al. have reported that the elevation of FSP27 (both isoforms with FSP27β 1000-fold higher than FSP27α) was likely to induce steatosis and liver injury in mouse model of chronic plus binge ethanol feeding. In this mouse model, the expression of CIDEA and CIDEB was not modified, hepatic FSP27 was strongly upregulated and the down regulation of FSP27 in hepatocytes prevented liver injury combined with the mitochondrial production of ROS. The authors also reported that hepatic expression of CIDEC mRNA increased more than 40-fold in samples from patients with alcoholic hepatitis and correlated with severity of the disease 19 . The authors further reported that the sustained FSP27 elevation in hepatocytes likely causes chronic liver injury and inflammation, and may subsequently induce fibrosis in a mouse model that combines chronic and acute-on chronic liver injury 19 .
Finally, we also report that the hepatic expression of CIDEB (at the mRNA level) is independent of obesity, as previously reported 31, 36 , and also independent of hepatic steatosis and steahepatitits in mouse and human studies. While the level of gene expression was stable, CIDEB was the most highly expressed among the 3 members of the CIDE family in hepatocytes (2000x more than CIDEA and 400x more than FSP27/CIDEC in mice and humans) and could be an important player in the development of hepatic steatosis since it regulates the formation of triacylglycerol-enriched VLDL particles 36 .
In this current study, we demonstrated that the hepatic expressions of the members of the CIDE family are differentially regulated according to the development and the severity of NAFLD in mouse and human studies. The gradual elevation of FSP27β/CIDEC2 expression with the development of hepatic steatosis and subsequent steatohepatitis reinforces our interest in this protein as a potential therapeutic target. It would need to be targeted only when robustly upregulated, and in a hepatocyte-specific manner in order to maintain its beneficial role in the storage of lipids in adipocytes 37 .
Material and Methods
Human samples. In this study, human samples (blood, liver biopsy) were from twenty-eight morbidly obese patients and five lean subjects. All information relative to the patients are described in Supplementary Methods, Table 1 and Ethics approval section.
Mice. Male mice were used in all experiments described in Supplementary Methods. All animal experiments were approved by the CIEPAL and Use committee.
Real-time quantitative PCR analysis has been performed as previously described 38, 39 and described in the Supplementary Methods.
Immunoblotting. Cells or frozen tissues were solubilized in lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 10 mM EDTA, 150 mM NaF, 2 mM sodium orthovanadate, 10 mM pyrophosphate, proteases inhibitors cocktail, NAFLD Activity Score (n) 0(5) 1(4)/2(4)/3(6) 5 (9) Grade of steatosis (n) 0(5) 1(4)/2(4)/3(6) 3 (9) Lobular inflammation (n) 0(5) 0(14) 1 (9) Hepatocellular ballooning (n) 0(5) 0(14) 1 (9) www.nature.com/scientificreports www.nature.com/scientificreports/ and 1% Triton X-100) for 45 min at 4 °C. Lysates were cleared (14 000 rpm, 15 min). Proteins were quantified (BCA Protein assay kit, 23225 Thermo Fisher Scientific Inc.), separated by SDS-PAGE and immunoblotted as previously described 38 . The proteins were probed with anti-CIDEA (NBP1-76950, Novus Biologicals), anti-FSP27 (ab77115, ab198204 Abcam), and anti-HSP90 (#4877, Cell Signaling) antibodies at 1 µg/mL. www.nature.com/scientificreports www.nature.com/scientificreports/ Cellular models and treatments. Down regulation of FSP27. Down regulation of FSP27 was achieved using ON-TARGET plus SMART pool technologies (L-040997, Mouse FSP27, NM_178373 or non-targeting siRNA as a control, Darmacon, CO) and Lipofectamine RNAiMAX technologies (MSS236551, Mouse FSP27 Life Technologies) in AML-12 hepatocytes (ATCC, CRL-2254). Following a 24-hour transfection, oleic acid (0.5 mM) was applied to cells for 16 hours. Cells were then rinsed twice with PBS and fixed with 4% formaldehyde solution. Lipid droplets were stained by Oil-Red O solution for 5 min. Microscope slides were prepared (x60 magnification) for lipid droplet quantification. The area of the lipid droplets was quantified (in pixels squared) and normalized by the number of nuclei on the slides.
Overexpression of FSP27β. HEPG2 cells (ATCC HB-8065) were transfected with pCMV-HA FSP27β or the empty plasmid (provided by Drs Xu Xu and Ann-Hwee Lee 18 ) using a Jet PEI-hepatocyte mix assay (102-05NOzyme). After 48 h, cells were treated with TNFα (20 ng/ml), actinomycin D (0.1 µg/ml) with TNFα (20 ng/ml) or palmitic acid (1 mM) for 16 h. Gene expression, cell viability and cell death were then evaluated as indicated.
MTT assay. The assay is dependent on the ability of viable cells to metabolize a water-soluble tetrazolium salt into a water-insoluble formazan product. Following the indicated treatments, cells were incubated for 2 h with 0.5 mg/mL MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) in serum-free medium (DMEM). After removing the supernatant, DMSO was added to completely dissolve the formazan product. Aliquots of the resulting solutions were transferred to 96-well plates and the absorbance was recorded at 550 nm using the microplate spectrophotometer system (ELX800, Bio-TEK instruments). Results are presented as a percentage of the control values.
Cell death. Flow cytometry was used to evaluate cell death following double staining with annexin-V-PE and 7-AAD according to the manufacturer's instructions (Annexin V-PE apoptosis detection kit I, BD Biosciences, Pont de claix, France). 
